However, no significant differences were observed for other clinical variables such as Body Mass Index (BMI), gender, LDL, statin usage, tumor progression, tumor stage, and tumor type in the anti-PD-1-treated group (Supplementary information, Fig. S1). The gene discussed is PDCD1; the disease is neoplasm.